Authors/Disclosures
|
Diego Garcia-Borreguero, MD
(Sleep Research Institute)
|
No disclosure on file |
|
|
No disclosure on file |
|
Richard P. Allen, PhD
(Johns Hopkins Univ.)
|
No disclosure on file |
|
John Winkelman, MD, PhD
|
John Winkelman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexza. John Winkelman has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Azurity. John Winkelman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Disc Medicine. An immediate family member of John Winkelman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Emalex. John Winkelman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentec. John Winkelman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Haleon. John Winkelman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Idorsia. John Winkelman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Noctrix. John Winkelman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Psychogenics. The institution of John Winkelman has received research support from American Regent. The institution of John Winkelman has received research support from Merck. John Winkelman has received publishing royalties from a publication relating to health care. John Winkelman has a non-compensated relationship as a Chair with International Restless Legs Syndrome Study Group that is relevant to AAN interests or activities. John Winkelman has a non-compensated relationship as a Member with Restless Legs Syndrome Foundation Scientific Medical Advisory Board that is relevant to AAN interests or activities. |
|
Matthew P. Wicklund, MD, FAAN
(UT Health San Antonio)
|
Dr. Wicklund has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amicus Therapeutics. Dr. Wicklund has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi-Genzyme. Dr. Wicklund has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta Therapeutics. Dr. Wicklund has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Spark Therapeutics. Dr. Wicklund has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ultragenyx. Dr. Wicklund has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Vertex Pharmaceuticals. The institution of Dr. Wicklund has received research support from Orphazyme. The institution of Dr. Wicklund has received research support from Muscular Dystrophy Association. The institution of Dr. Wicklund has received research support from Coalition to Cure Calpain 3. The institution of Dr. Wicklund has received research support from Sarepta Therapeutics. The institution of Dr. Wicklund has received research support from ML Bio. The institution of Dr. Wicklund has received research support from Alexion. The institution of Dr. Wicklund has received research support from Acceleron. The institution of Dr. Wicklund has received research support from Edgewise. The institution of Dr. Wicklund has received research support from Fulcrum. The institution of Dr. Wicklund has received research support from Roche-Genentech. The institution of Dr. Wicklund has received research support from Avidity. Dr. Wicklund has received research support from Harmony Bioscience. |
|
|
No disclosure on file |
|
|
No disclosure on file |
|
|
No disclosure on file |